Company: NCEL
Filing Date: 2025-02-10
Form Type: F-3
Source: 0001213900-25-011823
Chunk: 98

Company: NewcelX Ltd.
Filing Date: 2025-02-10
Form: F-3
Chunk 98
---
 other confidential information increases the risk that such trade secrets become known by
Kadimastem’s competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of
these agreements. Given that Kadimastem’s proprietary position is based, in part, on its know-how and trade secrets, a competitor’s
discovery of its trade secrets or other unauthorized use or disclosure would impair its competitive position and may have a material adverse
effect on its business.

Risks Related to Kadimastem’s Intellectual Property

Kadimastem has filed multiple patent applications and have a limited number of issued patents. There can be no assurance that any of its patent applications will result in issued patents. As a result, Kadimastem’s ability to protect its proprietary technology in the marketplace may be limited.

Kadimastem has filed patent
applications in countries worldwide. These applications cover a range of areas including: the U.S., EU, Israel and Japan. While several
patent applications have been granted, several are still pending. Unless and until its pending patent applications are issued, their protective
scope is impossible to determine. It is impossible to predict whether or how many of its patent applications will result in issued patents.
Even if pending applications are issued, they may be issued with coverage significantly narrower than what Kadimastem currently seek.

Kadimastem’s proprietary position for its product candidates currently depends upon patents protecting the method of use, which may not prevent a competitor or other third party from using the same product candidate for another use.

The primary patent based intellectual
property protection for Kadimastem’s product candidates will be any patents granted on the method of use and formulation. Kadimastem
does not have patents or patent applications covering its products as a composition of matter (i.e., compound claims).

Composition of matter patent
claims on the active pharmaceutical ingredient, or API, in pharmaceutical products are generally considered to be the favored form of
intellectual property protection for pharmaceutical products, as such patents provide protection without regard to any particular method
of use, manufacture or formulation of the API used. Method of use patent claims protect the use of a product for the specified method
and dosing. These types of patent claims do not prevent a competitor or other third party from making and marketing an identical API for
an indication that is outside the scope of the method claims or from developing a different dosing regimen. Moreover, even if competitors
or other third parties do not actively